Daniel Greenleaf is in a familiar position. The new president and CEO of BioScrip is tasked with turning around an underperforming home infusion company, which he did with both Coram and, more recently, with Home Solutions.
NEWARK, N.J. – U.S. Healthcare Supply, a national contract supplier for mail-order diabetes supplies, and two of its executives have agreed to pay the government more than $12.2 million to resolve allegations that they violated the False Claims Act.
DENVER – BioScrip reported net revenues of $238.5 million for the first quarter of 2016, compared to $244.4 million for the same period a year ago, a decrease of 2.4%. Adjusted EBITDA was $7.4 millionvs. $4.9 million.
ELMSFORD, N.Y. – BioScrip today reported third quarter revenues from continuing operations of $247.3 million, a 6.8% increase over the same period last year. Gross profit was $63.1 million, a 3.9% increase, and net loss was $24.2 million, the company reported.